EGF and non-small cell lung carcinoma: Approved for use following the completion of a first‐line chemotherapeutic75Utilizes a human recombinant epidermal growth factor (EGF) in order to stimulate an immune response against autologous EGF109Recent trials have demonstrated efficacy in lengthening the median overall survival of NSCLC patients with stable disease110